Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Mucormycosis is also known as zygomycosis which is a fatal but rare fungal infection caused due to group of fungus named as mucoromycetes. Furthermore, the fungus enters into the skin via wounds like cut, scrape, burn or other types of skin trauma. The fungal infection may affect anyone, but it is common in peoples with impaired immune system and may occur in any part of the body. Additionally, the cases of mucormycosis is also rising in patient which are getting treatments of COVID-19. The steroid medicines are commonly used in the management of disease condition in these patients as they are effective in management but they may impair the immune system and increase the blood sugar levels, which makes patient more prone to mucormycosis.
The United States mucormycosis market is witnessing tremendous growth during forecast period of 2021 to 2027. The risk factors for occurrence of mucormycosis is comprised of cancers, uncontrolled diabetes, neutropenia and organ transplant. The dynamic factors such as increase in organ and bone marrow transplant is propelling growth of United States mucormycosis market. The high surge in diabetic patients is also boosting growth of United States mucormycosis market. However, side effects of the drugs is hindering the growth of the United States mucormycosis market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the mucormycosis market. In addition, complete analysis of changes on mucormycosis expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on United States economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe.
The United States mucormycosis market is bifurcated into species, diagnosis method, drugs and distribution channel.
Based on species, the United States mucormycosis market is segmented into the rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other. In which apophysomyces is also contributing to the growth of United States mucormycosis market. The apophysomyces is a genus of filamentous fungi that are generally found in soil and decaying vegetation. Species normally grow in tropical to subtropical regions. The genus apophysomyces previously was monospecific comprised only the types apophysomyces elegans.
Based on diagnosis methods, the United States mucormycosis market is bifurcated into the magnetic resonance imaging, computed tomography, tissue biopsy and others. The magnetic resonance imaging is also contributing to the growth of United States mucormycosis market. The high usage of steroids during management of COVID-19 patients is propelling the growth of United States mucormycosis market. The rising technological advancement is also boosting growth of United States mucormycosis market.
Based of drugs, the United States mucormycosis market is comprised of the Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. In which voriconazole is also contributing to the growth of United States mucormycosis market. The increasing cases of immune suppressant diseases is propelling growth of United States mucormycosis market. The growing cases of mucormycosis is also boosting growth of United States mucormycosis market.
Based on distribution channel, the United States mucormycosis market is bifurcated into the hospital pharmacies, retail pharmacies and online pharmacies. In which retail pharmacies is also contributing to the growth of United States mucormycosis market. The growing patient population is propelling growth of United States mucormycosis market. The growing use of steroids is also boosting growth of United States mucormycosis market.
The major key players such as Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums And Vaccines, Bdr Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited and Tlc Pharma Labs among others.
June 2021: Celon Laboratories launched an alternative drug, Amphotericin B Emulsion for the treatment of mucormycosis.
May 2021: TLC Pharma, a clinical-stage specialty pharmaceutical company, received approval for the New Drug Application (NDA) for Amphotericin B liposome injection (AmphoTLC), form the Central Drugs Standard Control Organization (CDSCO) of India. The drug can be used in the treatment of fungal infections including mucormycosis infections.
2020: Pfizer Inc. in association with its partner Basilea Pharmaceutica Ltd., launched Cresemba (isavuconazole). The drug is used in mucormycosis and invasive aspergillosis.
September 2019: U.S. FDA granted Fast Track designations for intravenous (IV) and oral formulations for fosmanogepix (APX001) developed, by Amplyx Pharmaceuticals.
The report analyses the mucormycosis market based on species, diagnosis method, drugs and distribution channel. Various species of fungi covered in mucormycosis market are rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other. By diagnosis method, the market is segmented into the magnetic resonance imaging, computed tomography, tissue biopsy and other. Based on drugs the market is segmented into Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. Based on distribution channel, the market is segmented into the hospital pharmacies, retail pharmacies and online pharmacies. The report also analyses the impact of COVID-19 on the market and it concludes that the COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe. The report also comprised of major key players operating in the market.
Why to buy this report
